Spyglass Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of chronic ophthalmic diseases through its innovative drug delivery platform. The company's primary focus is on addressing the challenges of patient compliance and the limitations of traditional eye drop therapies, which are often the standard of care for conditions like glaucoma. Spyglass Pharma's core technology is a proprietary drug-eluting intraocular lens (IOL) platform. This system is designed to be implanted during routine cataract surgery, providing a controlled, long-term release of medication directly into the eye. By automating drug delivery at the source, the company aims to provide a more consistent and effective treatment regimen for patients suffering from glaucoma and ocular hypertension, significantly reducing the burden of daily self-administration. The company's lead product candidate utilizes this platform to deliver bimatoprost, a well-established medication for lowering intraocular pressure, over an extended period. This approach seeks to eliminate the high rates of non-compliance associated with topical drops. Spyglass Pharma is currently advancing its platform through clinical trials to establish the safety and efficacy of its delivery system. Headquartered in Aliso Viejo, California, Spyglass Pharma was co-founded by industry veterans and clinicians with extensive experience in ophthalmology and medical device development. The company is supported by leading venture capital investors and continues to explore the application of its technology to a broader range of ocular conditions beyond its initial focus on glaucoma.
Book value of equity per share effectively indicates a firm's net asset value (total assets - total liabilities) on a per-share basis. References: Below 1: the company is trading below its equity. Equal to 1: the company is trading at the exact value of its equity. Above 1: The company is trading above its equity.
Shows how much the market values every dollar of the company's sales.
Shows how much the market values every dollar of the company's EBITDA.
The price-to-cash flow (P/CF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its operating cash flow per share. The ratio uses operating cash flow (OCF), which adds back non-cash expenses such as depreciation and amortization to net income. P/CF is especially useful for valuing stocks that have positive cash flow but are not profitable because of large non-cash charges.
The price-to-free cash flow (P/FCF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its free cash flow per share. This metric is very similar to the valuation metric of price to cash flow but is considered a more exact measure because it uses free cash flow, which subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.
The price-to-earnings ratio is the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS) and is used by investors and analysts to determine the relative value of a company's shares in an apples-to-apples comparison.
Book value per share (BVPS) takes the ratio of a firm's common equity divided by its number of shares outstanding.
Earnings per share (EPS) is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability. EPS indicates how much money a company makes for each share of its stock and is a widely used metric for estimating corporate value.
...and much more!